A pilot study of 2% tofacitinib cream with narrowband ultraviolet B for the treatment of facial vitiligo

Jacqueline McKesey; Amit G. Pandya

doi:10.1016/j.jaad.2019.04.032

A pilot study of 2% tofacitinib cream with narrowband ultraviolet B for the treatment of facial vitiligo

Jacqueline McKesey, Amit G. Pandya

Research output: Contribution to journal › Article › peer-review

Original language	English (US)
Pages (from-to)	646-648
Number of pages	3
Journal	Journal of the American Academy of Dermatology
Volume	81
Issue number	2
DOIs	https://doi.org/10.1016/j.jaad.2019.04.032
State	Published - Aug 2019

ASJC Scopus subject areas

Dermatology

Access to Document

10.1016/j.jaad.2019.04.032

Cite this

@article{499411394bcb48ca807f9e8ed0e05ef0,

title = "A pilot study of 2% tofacitinib cream with narrowband ultraviolet B for the treatment of facial vitiligo",

author = "Jacqueline McKesey and Pandya, {Amit G.}",

note = "Funding Information: Conflicts of interest: Dr Pandya is a consultant for Pfizer, maker of tofacitinib, and serves as the principal investigator for a vitiligo study with a new drug funded by Pfizer. Dr McKesey has no conflicts of interest to disclose. Funding sources: None. Conflicts of interest: Dr Pandya is a consultant for Pfizer, maker of tofacitinib, and serves as the principal investigator for a vitiligo study with a new drug funded by Pfizer. Dr McKesey has no conflicts of interest to disclose.",

year = "2019",

month = aug,

doi = "10.1016/j.jaad.2019.04.032",

language = "English (US)",

volume = "81",

pages = "646--648",

journal = "Journal of the American Academy of Dermatology",

issn = "0190-9622",

publisher = "Mosby Inc.",

number = "2",

}

TY - JOUR

T1 - A pilot study of 2% tofacitinib cream with narrowband ultraviolet B for the treatment of facial vitiligo

AU - McKesey, Jacqueline

AU - Pandya, Amit G.

N1 - Funding Information: Conflicts of interest: Dr Pandya is a consultant for Pfizer, maker of tofacitinib, and serves as the principal investigator for a vitiligo study with a new drug funded by Pfizer. Dr McKesey has no conflicts of interest to disclose. Funding sources: None. Conflicts of interest: Dr Pandya is a consultant for Pfizer, maker of tofacitinib, and serves as the principal investigator for a vitiligo study with a new drug funded by Pfizer. Dr McKesey has no conflicts of interest to disclose.

PY - 2019/8

Y1 - 2019/8

UR - http://www.scopus.com/inward/record.url?scp=85068794064&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85068794064&partnerID=8YFLogxK

U2 - 10.1016/j.jaad.2019.04.032

DO - 10.1016/j.jaad.2019.04.032

M3 - Article

C2 - 31009664

AN - SCOPUS:85068794064

SN - 0190-9622

VL - 81

SP - 646

EP - 648

JO - Journal of the American Academy of Dermatology

JF - Journal of the American Academy of Dermatology

IS - 2

ER -

A pilot study of 2% tofacitinib cream with narrowband ultraviolet B for the treatment of facial vitiligo

ASJC Scopus subject areas

Access to Document

Other files and links

Cite this